Hormonal Contraception and Risk of Cardiometabolic Disease in Women with HIV
Conclusion: Our results suggest that cardiovascular risk should be considered when selecting contraception for women with HIV.PMID:38484324 | DOI:10.1089/jwh.2023.0230 (Source: Atherosclerosis)
Source: Atherosclerosis - March 14, 2024 Category: Cardiology Authors: Jamison Norwood Cathy A Jenkins Manasa Bhatta Megan Turner Aihua Bian Jeffrey Nelson Imani Ransby Dana Hughes John R Koethe Timothy R Sterling Bryan E Shepherd Jessica L Castilho Source Type: research
A Contemporary View of Menopausal Hormone Therapy
Obstet Gynecol. 2024 Mar 14. doi: 10.1097/AOG.0000000000005553. Online ahead of print.ABSTRACTEnthusiasm for the use of hormones to ameliorate symptoms of perimenopause and menopause has waxed and waned over the years. Both treatment for symptoms and training of women's health care practitioners in the management of menopause have sharply declined since publication of the Women's Health Initiative initial results in 2002. Findings from that trial, which treated a population of older, asymptomatic patients, have been extrapolated over the past 21 years to all estrogen products, all menopausal women, and all delivery mechani...
Source: Obstetrics and Gynecology - March 14, 2024 Category: OBGYN Authors: Barbara Levy James A Simon Source Type: research
Hormonal Contraception and Risk of Cardiometabolic Disease in Women with HIV
Conclusion: Our results suggest that cardiovascular risk should be considered when selecting contraception for women with HIV.PMID:38484324 | DOI:10.1089/jwh.2023.0230 (Source: Atherosclerosis)
Source: Atherosclerosis - March 14, 2024 Category: Cardiology Authors: Jamison Norwood Cathy A Jenkins Manasa Bhatta Megan Turner Aihua Bian Jeffrey Nelson Imani Ransby Dana Hughes John R Koethe Timothy R Sterling Bryan E Shepherd Jessica L Castilho Source Type: research
A Contemporary View of Menopausal Hormone Therapy
Obstet Gynecol. 2024 Mar 14. doi: 10.1097/AOG.0000000000005553. Online ahead of print.ABSTRACTEnthusiasm for the use of hormones to ameliorate symptoms of perimenopause and menopause has waxed and waned over the years. Both treatment for symptoms and training of women's health care practitioners in the management of menopause have sharply declined since publication of the Women's Health Initiative initial results in 2002. Findings from that trial, which treated a population of older, asymptomatic patients, have been extrapolated over the past 21 years to all estrogen products, all menopausal women, and all delivery mechani...
Source: Obstetrics and Gynecology - March 14, 2024 Category: OBGYN Authors: Barbara Levy James A Simon Source Type: research
A Contemporary View of Menopausal Hormone Therapy
Obstet Gynecol. 2024 Mar 14. doi: 10.1097/AOG.0000000000005553. Online ahead of print.ABSTRACTEnthusiasm for the use of hormones to ameliorate symptoms of perimenopause and menopause has waxed and waned over the years. Both treatment for symptoms and training of women's health care practitioners in the management of menopause have sharply declined since publication of the Women's Health Initiative initial results in 2002. Findings from that trial, which treated a population of older, asymptomatic patients, have been extrapolated over the past 21 years to all estrogen products, all menopausal women, and all delivery mechani...
Source: Obstetrics and Gynecology - March 14, 2024 Category: OBGYN Authors: Barbara Levy James A Simon Source Type: research
A Contemporary View of Menopausal Hormone Therapy
Obstet Gynecol. 2024 Mar 14. doi: 10.1097/AOG.0000000000005553. Online ahead of print.ABSTRACTEnthusiasm for the use of hormones to ameliorate symptoms of perimenopause and menopause has waxed and waned over the years. Both treatment for symptoms and training of women's health care practitioners in the management of menopause have sharply declined since publication of the Women's Health Initiative initial results in 2002. Findings from that trial, which treated a population of older, asymptomatic patients, have been extrapolated over the past 21 years to all estrogen products, all menopausal women, and all delivery mechani...
Source: Obstetrics and Gynecology - March 14, 2024 Category: OBGYN Authors: Barbara Levy James A Simon Source Type: research
A Contemporary View of Menopausal Hormone Therapy
Obstet Gynecol. 2024 Mar 14. doi: 10.1097/AOG.0000000000005553. Online ahead of print.ABSTRACTEnthusiasm for the use of hormones to ameliorate symptoms of perimenopause and menopause has waxed and waned over the years. Both treatment for symptoms and training of women's health care practitioners in the management of menopause have sharply declined since publication of the Women's Health Initiative initial results in 2002. Findings from that trial, which treated a population of older, asymptomatic patients, have been extrapolated over the past 21 years to all estrogen products, all menopausal women, and all delivery mechani...
Source: Obstetrics and Gynecology - March 14, 2024 Category: OBGYN Authors: Barbara Levy James A Simon Source Type: research
A Contemporary View of Menopausal Hormone Therapy
Obstet Gynecol. 2024 Mar 14. doi: 10.1097/AOG.0000000000005553. Online ahead of print.ABSTRACTEnthusiasm for the use of hormones to ameliorate symptoms of perimenopause and menopause has waxed and waned over the years. Both treatment for symptoms and training of women's health care practitioners in the management of menopause have sharply declined since publication of the Women's Health Initiative initial results in 2002. Findings from that trial, which treated a population of older, asymptomatic patients, have been extrapolated over the past 21 years to all estrogen products, all menopausal women, and all delivery mechani...
Source: Obstetrics and Gynecology - March 14, 2024 Category: OBGYN Authors: Barbara Levy James A Simon Source Type: research
TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway
CONCLUSION: TET3 promoted the DNA demethylation modification in the SHP2 promoter and activated SHP2, thus activating the EGFR/ERK pathway and leading to EC progression.PMID:38456588 | DOI:10.3802/jgo.2024.35.e64 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - March 8, 2024 Category: OBGYN Authors: Fen Xue Lifen Liu Xueqiang Tao Weipei Zhu Source Type: research
TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway
CONCLUSION: TET3 promoted the DNA demethylation modification in the SHP2 promoter and activated SHP2, thus activating the EGFR/ERK pathway and leading to EC progression.PMID:38456588 | DOI:10.3802/jgo.2024.35.e64 (Source: Cancer Control)
Source: Cancer Control - March 8, 2024 Category: Cancer & Oncology Authors: Fen Xue Lifen Liu Xueqiang Tao Weipei Zhu Source Type: research
TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway
CONCLUSION: TET3 promoted the DNA demethylation modification in the SHP2 promoter and activated SHP2, thus activating the EGFR/ERK pathway and leading to EC progression.PMID:38456588 | DOI:10.3802/jgo.2024.35.e64 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - March 8, 2024 Category: OBGYN Authors: Fen Xue Lifen Liu Xueqiang Tao Weipei Zhu Source Type: research
